TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03556228: VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Sponsor: VM Oncology, LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 242 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$8,875,020

Rescue Site Savings

+$5,851,230

Unlock Full NCT03556228 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03556228 Rescue Dossier →